NCT04322591招募中不适用
Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced Non-small Cell Lung Cancer ( Poseidon Study）
Hunan Province Tumor Hospital1 个研究点 分布在 1 个国家目标入组 70 人开始时间: 2020年3月24日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 70
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in RET Fusion Positive Advanced Non-small Cell Lung Cancer.
详细描述
This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus the PD-1 antibody in RET Fusion Positive Advanced Non-small Cell Lung Cancer. We aim to enrolled 100 patients in this study, the primary endpoint was PFS.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
- •RET Fusion Positive
- •First Diagnosis and Treatment
- •Treatment Plan is Chemotherapy or Chemotherapy plus PD-1 antibody
排除标准
- •- Patients received antitumor treatment before
- •Patients with contraindication of chemotherapy
- •Pregnant or breast feeding women
结局指标
主要结局
PFS
时间窗: may 2020- may 2021 (1 year)
Progression free survival time
次要结局
- ORR(may 2020- may 2021 (1 year))
- OS(may 2020- may 2021 (1 year))
研究者
Yongchang Zhang
professor
Hunan Province Tumor Hospital
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLCNon Small Cell Lung CancerNCT04324125Hunan Province Tumor Hospital70
Unknown
2 期
PD-1 Antibody + XELOX in 1st Line Serum A-fetoprotein (AFP)-Elevated Gastric or Gastroesophageal Junction AdenocarcinomaGastric or Gastroesophageal Junction AdenocarcinomaAFPNCT04098796China Medical University, China30
Unknown
2 期
Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic CholangiocarcinomaIntrahepatic Cholangiocarcinoma by AJCC V8 StageNCT04413734Zhejiang University120
进行中（未招募）
2 期
Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal CarcinomaRecurrent Nasopharyngeal CarcinomaNCT03930498Sun Yat-sen University68
招募中
2 期
Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCCEsophageal Squamous Cell Carcinoma Stage IIEsophageal Squamous Cell Carcinoma Stage IIINCT04973306Shanghai Zhongshan Hospital176